1.790USDMkt Cap: 76.62M USDP/E: —Last update: 2026-05-21
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generat…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap76.62M USD
Enterprise Value-18.71M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-77.91M USD
Revenue/Share—
Last Price1.790 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees74
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.96
PEG—
EV/EBITDA0.23
EV/Revenue—
P/S—
P/B0.50
EPS (TTM)-2.00
EPS (Forward)-1.87
52W Range
1.73052% of range1.845
52W High1.845 USD
52W Low1.730 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-69.24%
ROA-60.06%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-63.66M USD
CapEx (TTM)1.67M USD
FCF Margin—
FCF Yield-51.27%
Net Debt-95.32M USD
Net Debt/EBITDA1.18
Balance Sheet
Debt/Equity0.02
Current Ratio8.98
Quick Ratio8.84
Book Value/Sh3.555 USD
Cash/Share2.283 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)11.50 USD
Target Range7.000 USD – 19.00 USD
# Analysts6
Ownership
Shares Out.42.80M
Float27.97M
Insiders15.40%
Institutions47.04%
Short Interest
Short Ratio3.0d
Short % Float8.60%
Short % Out.5.76%
Shares Short2.46M
Short (prev mo.)2.19M
Technical
SMA 501.725 (+3.8%)
SMA 2001.834 (-2.4%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)355.17K
Avg Vol (10d)479.84K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—